000403 Stock Overview
Pacific Shuanglin Bio-pharmacy Co., Ltd. engages in research, development, production, and sales of blood products in China.
Snowflake Score | |
---|---|
Valuation | 3/6 |
Future Growth | 2/6 |
Past Performance | 4/6 |
Financial Health | 6/6 |
Dividends | 2/6 |
Pacific Shuanglin Bio-pharmacy Co., LTD Competitors
Price History & Performance
Historical stock prices | |
---|---|
Current Share Price | CN¥25.30 |
52 Week High | CN¥31.25 |
52 Week Low | CN¥17.49 |
Beta | 0.42 |
11 Month Change | -6.85% |
3 Month Change | -15.10% |
1 Year Change | 30.55% |
33 Year Change | -21.82% |
5 Year Change | 65.78% |
Change since IPO | 2,586.72% |
Recent News & Updates
We Think Pacific Shuanglin Bio-pharmacy (SZSE:000403) Can Stay On Top Of Its Debt
Jul 22Is Now The Time To Put Pacific Shuanglin Bio-pharmacy (SZSE:000403) On Your Watchlist?
May 24Shareholder Returns
000403 | CN Biotechs | CN Market | |
---|---|---|---|
7D | 3.4% | 3.5% | -0.6% |
1Y | 30.5% | -22.4% | -22.0% |
Return vs Industry: 000403 exceeded the CN Biotechs industry which returned -22.4% over the past year.
Return vs Market: 000403 exceeded the CN Market which returned -22% over the past year.
Price Volatility
000403 volatility | |
---|---|
000403 Average Weekly Movement | 5.1% |
Biotechs Industry Average Movement | 5.9% |
Market Average Movement | 5.7% |
10% most volatile stocks in CN Market | 9.0% |
10% least volatile stocks in CN Market | 3.9% |
Stable Share Price: 000403 has not had significant price volatility in the past 3 months.
Volatility Over Time: 000403's weekly volatility (5%) has been stable over the past year.
About the Company
Founded | Employees | CEO | Website |
---|---|---|---|
1993 | 2,426 | Xiankui Rong | www.slbiop.com |
Pacific Shuanglin Bio-pharmacy Co., Ltd. engages in research, development, production, and sales of blood products in China. Its lead products include human serum albumin, human immunoglobulin, intravenous human immunoglobulin (PH4), hepatitis B human immunoglobulin, tetanus human immunoglobulin, rabies patient immunoglobulin, and human coagulation factor. addition, it engages in the investment, consultation, and technology promotion of pharmaceutical and biotechnology development projects; and electronic product information consultation.
Pacific Shuanglin Bio-pharmacy Co., LTD Fundamentals Summary
000403 fundamental statistics | |
---|---|
Market cap | CN¥18.48b |
Earnings (TTM) | CN¥677.68m |
Revenue (TTM) | CN¥2.50b |
27.3x
P/E Ratio7.4x
P/S RatioIs 000403 overvalued?
See Fair Value and valuation analysisEarnings & Revenue
000403 income statement (TTM) | |
---|---|
Revenue | CN¥2.50b |
Cost of Revenue | CN¥1.21b |
Gross Profit | CN¥1.30b |
Other Expenses | CN¥618.88m |
Earnings | CN¥677.68m |
Last Reported Earnings
Mar 31, 2024
Next Earnings Date
Aug 28, 2024
Earnings per share (EPS) | 0.93 |
Gross Margin | 51.79% |
Net Profit Margin | 27.07% |
Debt/Equity Ratio | 7.0% |
How did 000403 perform over the long term?
See historical performance and comparison